share_log

HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Raises Price Target to $160

Benzinga ·  May 2 07:00

HC Wainwright & Co. analyst Andrew Fein maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $150 to $160.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment